Welcome to our dedicated page for 10X Genomics SEC filings (Ticker: TXG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for 10x Genomics, Inc. (NASDAQ: TXG), a life science technology company specializing in single cell and spatial biology. Through these filings, investors and researchers can review the company’s regulatory disclosures, including annual and quarterly reports and current reports on material events.
10x Genomics’ Class A common stock is registered on The Nasdaq Stock Market LLC under the symbol TXG, as noted in its Form 8-K filings. The company uses SEC filings, along with its website, press releases, public conference calls, webcasts and social media accounts, as channels for disclosing information and for complying with Regulation FD. Form 8-K filings have addressed topics such as quarterly financial results and changes in certain executive roles.
Key SEC documents for TXG include annual reports on Form 10-K and quarterly reports on Form 10-Q, which contain detailed information about revenue by product type and geography, gross margin, operating expenses, cash and marketable securities, and risk factors. Current reports on Form 8-K provide timely updates on specific events, such as earnings releases or leadership changes. Together, these filings give a structured view of how 10x Genomics’ single cell and spatial biology business is performing and evolving.
On Stock Titan, users can view TXG filings as they are made available from EDGAR and use AI-powered summaries to interpret complex sections, such as revenue breakdowns, operating results and risk disclosures. Filings related to topics like license and royalty revenue, services, and geographic revenue distribution can be examined to understand the company’s financial profile. This page also offers convenient access to insider and governance-related filings, helping users track corporate developments over time.
TXG filed a Form 144 reporting a proposed sale of common stock by Morgan Stanley Smith Barney LLC Executive Financial Services. The filing lists restricted stock lots of 3,740 shares dated
Benjamin J. Hindson submitted a Form 144 reporting a proposed sale of 8,301 shares of common stock, listed with Morgan Stanley Smith Barney LLC and dated
TXG files a Form 144 disclosing an intended sale of 25,784 shares of Common Stock tied to a Restricted Stock Unit Grant dated
TXG files a Form 144 reporting a proposed sale of Common Stock. The notice lists 23,767 shares associated with a Restricted Stock Unit grant dated
10x Genomics, Inc. is a life sciences technology company focused on single cell, spatial and in situ analysis through its Chromium, Visium and Xenium platforms, supported by software like Cell Ranger, Loupe Browser and Xenium Explorer. In 2025 it acquired Scale Biosciences, adding QuantumScale single cell kits.
For the year ended December 31, 2025, revenue was $642.8 million, up 5% from $610.8 million in 2024, while net loss narrowed to $43.5 million from $182.6 million. The company sold 1,007 instruments and 424,000 consumable reactions in 2025 and estimates a total addressable market above $21 billion. Key risks include dependence on academic and government research funding (notably NIH), intense competition in genomics tools, potential pricing pressure, trade and tariff exposure, and execution challenges in entering clinical and diagnostic markets.
10x Genomics reported modest revenue growth but sharply improved profitability for 2025. Revenue was $166.0 million in Q4 2025, up 1% year over year, with full-year revenue of $642.8 million, a 5% increase from 2024. Excluding $44.1 million of non-recurring patent litigation settlement revenue, full-year revenue was $598.7 million, a 2% decline.
Q4 gross margin improved to 68% and full-year gross margin to 69%. Operating expenses fell 18% in Q4 and 17% for the year, helped by lower legal and personnel costs and a $49.9 million litigation settlement gain. Net loss narrowed to $16.3 million in Q4 2025 from $49.0 million a year earlier, and to $43.5 million for 2025 from $182.6 million in 2024.
The company ended 2025 with $523.4 million in cash, cash equivalents and marketable securities. For 2026, 10x Genomics guides to revenue of $600–$625 million, which represents 0% to 4% growth versus 2025 after excluding non-recurring patent-related revenue.
10x Genomics, Inc. filed a report stating that it has issued a press release with preliminary, unaudited select financial results for the fourth quarter and fiscal year ended December 31, 2025. The press release, dated January 11, 2026 and attached as Exhibit 99.1, covers key financial information for that quarter and the full year. The company notes that this information is being furnished rather than filed under securities laws, which affects how it is treated for liability and incorporation into other documents.